– Cardiovascular disease (CVD) remains world’s biggest killer, claiming 18.6 million lives per year GENEVA, Sept. 28, 2021 /PRNewswire/ — On World Heart Day, 29 September 2021, the World Heart Federation (WHF) is calling on the international community to bring digital cardiovascular health services to millions worldwide. COVID-19 has seen an explosion in telemedicine, […]
Coronary/Structural Heart
Foldax Completes Enrollment in Early Feasibility Study for TRIA Biopolymer Surgical Aortic Heart Valve
SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced completion of enrollment in the U.S. early feasibility study of the TRIA™ surgical aortic heart valve. The TRIA valve reimagines the heart valve by combining the company’s proprietary biopolymer – LifePolymer™ – with an innovative valve design intended to resist calcification, withstand stresses […]
Neovasc REDUCER-I Study Published in EuroIntervention Journal
VANCOUVER and MINNEAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)” in the September 2021 issue of the journal EuroIntervention. […]
Nanowear Receives FDA 510(k) Platform Clearance to Implement Forthcoming AI-based Diagnostics in its Closed Loop Hospital-at-Home Network
NEW YORK–(BUSINESS WIRE)–Nanowear, a leading hospital-at-home and remote diagnostic platform informed by proprietary cloth nanotechnology and AI, today announced that it received its third FDA 510(k) clearance and first software-only clearance as an end-to-end digital platform, illustrating unique capabilities available to enterprise customer channels across a broad spectrum of diagnostic […]
Stealth BioTherapeutics Presents Positive Elamipretide Data in Pediatric Cardiology at International Society for Heart Research North American Section Meeting 2021
Elamipretide data demonstrated improvement in mitochondrial function in pediatric cardiomyopathy BOSTON, Sept. 28, 2021 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of positive elamipretide data showing improvements in mitochondrial respiration […]
Zebra Medical Vision Secures 8th FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering
This latest milestone helps Zebra-Med expand its mission of screening populations at scale with its AI-based solutions, promoting early and preventative healthcare treatment. The CAC solution analyzes already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with […]
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
Pivotal UNIVERSE study published in the Journal of the American Heart Association Data included in recent New Drug Application submitted to FDA for two pediatric indications RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment […]
SeqLL Announces Publication of a New Blood-Based RNA Sequencing Method to Detect Coronary Artery Disease
GW-Led Research uses SeqLL’s tSMS® platform to identify novel signature for detection of coronary artery disease WOBURN, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel […]
Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease
Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol Comprehensive Off-Target Editing Analysis Using Industry Leading Methods, ONE-seq and Digenome-seq Showed No Off-Target Editing Across 244 Potential Sites in Human Liver Cells Data Support Continued Advancement of VERVE-101 Toward IND Submission […]
FDA APPROVES ABBOTT’S EPIC™ PLUS TISSUE VALVES FOR PEOPLE IN NEED OF MITRAL OR AORTIC VALVE REPLACEMENT
– New enhancements to Abbott’s Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures – Epic Plus designed to help patients with more complex cases of aortic or mitral regurgitation or […]



